Reuters logo
BRIEF-Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications
May 3, 2017 / 8:49 PM / 5 months ago

BRIEF-Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications

May 3 (Reuters) - Karyopharm Therapeutics Inc

* Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications

* Karyopharm Therapeutics Inc - Karyopharm to receive $1 million upfront payment

* Karyopharm Therapeutics Inc - Karyopharm then eligible to receive up to $43.5 million in future milestones, plus royalties Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below